You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 240 No. 15, October 6, 1978 TABLE OF CONTENTS
  JAMA
  •  Online Features
  ARTICLE
 This Article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA

Doxorubicin cardiotoxicity. Serial endomyocardial biopsies and systolic time intervals

M. A. Friedman, M. J. Bozdech, M. E. Billingham and A. K. Rider

Doxorubicin, whose dose-limiting toxicity is cardiomyopathy, was given to four cancer patients. Endomyocardial biopsy specimens and test results of cardiac function were obtained before, during, and after treatment. The biopsy specimens were examined by light and electron microscopy and were graded blindly. Evidence of specific doxorubicin injury was found in 3/4 patients with as little as 180 mg/sq m of the drug and became progressively more severe with higher doses. All test results of cardiac function, including systolic time intervals, remained normal. These data suggest that a specific, progressive subclinical injury to the heart occurs with doxorubicin therapy, which cannot be reliably detected by routine tests. This potential risk must be taken into account with the use of doxorubicin, especially when combined with synergistic agents.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

A Review of the Cardiovascular Effects of Oncology Agents
Frei and Soefje
Journal of Pharmacy Practice 2008;21:146-158.
ABSTRACT  

Increase in Mrp1 expression and 4-hydroxy-2-nonenal adduction in heart tissue of Adriamycin-treated C57BL/6 mice.
Jungsuwadee et al.
Molecular Cancer Therapeutics 2006;5:2851-2860.
ABSTRACT | FULL TEXT  

Is the Myofibrillarlytic Myocyte a Forme Fruste Apoptotic Myocyte?
Narula et al.
Ann. Thorac. Surg. 2005;79:1333-1337.
ABSTRACT | FULL TEXT  

Weekly paclitaxel combined with pegylated liposomal doxorubicin (CaelyxTM) given every 4 weeks: dose-finding and pharmacokinetic study in patients with advanced solid tumors
Briasoulis et al.
Ann Oncol 2004;15:1566-1573.
ABSTRACT | FULL TEXT  

Subclinical Late Cardiomyopathy After Doxorubicin Therapy for Lymphoma in Adults
Hequet et al.
JCO 2004;22:1864-1871.
ABSTRACT | FULL TEXT  

Attenuation of Doxorubicin Chronic Toxicity in Metallothionein-overexpressing Transgenic Mouse Heart
Sun et al.
Cancer Res. 2001;61:3382-3387.
ABSTRACT | FULL TEXT  

A small animal model of non-ischemic cardiomyopathy and its evaluation by transthoracic echocardiography
Schwarz et al.
Cardiovasc Res 1998;39:216-223.
ABSTRACT | FULL TEXT  

Anthracycline Cardiomyopathy: Pathophysiology and Case Reports
Brown and Hammond
Journal of Pediatric Oncology Nursing 1985;2:8-17.
 





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1978 American Medical Association. All Rights Reserved.